Baidu
map

Ren Fail:缺铁是血液透析患者5年全因死亡率的重要预测因子

2021-08-17 MedSci原创 MedSci原创 发表于上海

缺铁(低TSAT、铁或铁蛋白)是HD患者5年全因死亡率的重要预测因子。

缺铁在晚期肾病患者中很常见,尤其是那些需要血液透析 (HD) 的患者。事实上,铁对血管平滑肌细胞转化影响的研究表明它与内壁钙化有关,因此铁浓度可能与血管钙化的严重程度和 HD 患者的死亡率有关。而且,高冠状动脉钙化评分(CACS)可能也与接受血液透析(HD)的患者的高死亡率有关。

近期,《Renal Failure》发表了一篇临床研究,旨在调查HD患者中铁、CACS和死亡率之间的关系,结果发现较低的TSAT是CACS400的独立预测因子,缺铁(低TSAT、铁或铁蛋白)是HD患者5年全因死亡率的重要预测因子。

该研究纳入了173名持续接受HD的患者,并在基线时获得了两组患者的实验室数据和Agatston's CACS:CACS≥400的患者(n=109)和CACS<400的患者(n=64),后面进行了CACS≥400时死亡率的逻辑回归分析和Cox比例风险分析。

参与者的中位(四分位距)年龄和透析持续时间分别为67(60-75)岁和73(37-138)个月。CACS≥400的参与者的血清铁(Fe)和转铁蛋白饱和度(TSAT)水平显着低于CACS<400的参与者,但各组之间的血清铁蛋白浓度没有差异。TSAT≥21%与CACS≥400显着相关(RR=0.46,p<0.05)。

TSAT≥17%、Fe≥63µg/dL和铁蛋白≥200ng/mL是HD患者5年全因死亡率的重要预测因子,独立于全因死亡率的常规风险因素(p<0.05)。

转铁蛋白饱和度≥17%和<17%的参与者的Kaplan-Meier 5年累积生存曲线

TSAT:转铁蛋白饱和度

血清铁≥63和<63µg/dL的参与者的Kaplan-Meier5年累积生存曲线

Fe:血清铁

所有参与者的血清CRP、TSAT、Fe和铁蛋白的散点图矩阵

 

该研究确定了HD患者中铁、CACS和死亡率之间的关联,发现较低的TSAT是CACS400的独立预测因子,缺铁(低TSAT、铁或铁蛋白)是HD患者5年全因死亡率的重要预测因子。

原文出处:Mizuiri S, Nishizawa Y, Doi T, Yamashita K, Shigemoto K, Usui K, Arita M, Naito T, Doi S, Masaki T. Iron, coronary artery calcification, and mortality in patients undergoing hemodialysis. Ren Fail. 2021 Dec;43(1):371-380. doi: 10.1080/0886022X.2021.1880937. PMID: 33596750; PMCID: PMC7894440.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1251563, encodeId=054c125156365, content=<a href='/topic/show?id=874529332ba' target=_blank style='color:#2F92EE;'>#全因死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29332, encryptionId=874529332ba, topicName=全因死亡率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262561, encodeId=7bb31262561b3, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310771, encodeId=efcc1310e711e, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395183, encodeId=c43d1395183a8, content=<a href='/topic/show?id=c268e940840' target=_blank style='color:#2F92EE;'>#缺铁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79408, encryptionId=c268e940840, topicName=缺铁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570666, encodeId=f11d15e066667, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008892, encodeId=dc3b10088923d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210115/3496e0581a8a4aec93961012392656e4/fd1698e580a54f3caacf567878f77f53.jpg, createdBy=dd5a5211014, createdName=unlobotomy, createdTime=Wed Aug 18 06:01:17 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1251563, encodeId=054c125156365, content=<a href='/topic/show?id=874529332ba' target=_blank style='color:#2F92EE;'>#全因死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29332, encryptionId=874529332ba, topicName=全因死亡率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262561, encodeId=7bb31262561b3, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310771, encodeId=efcc1310e711e, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395183, encodeId=c43d1395183a8, content=<a href='/topic/show?id=c268e940840' target=_blank style='color:#2F92EE;'>#缺铁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79408, encryptionId=c268e940840, topicName=缺铁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570666, encodeId=f11d15e066667, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008892, encodeId=dc3b10088923d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210115/3496e0581a8a4aec93961012392656e4/fd1698e580a54f3caacf567878f77f53.jpg, createdBy=dd5a5211014, createdName=unlobotomy, createdTime=Wed Aug 18 06:01:17 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1251563, encodeId=054c125156365, content=<a href='/topic/show?id=874529332ba' target=_blank style='color:#2F92EE;'>#全因死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29332, encryptionId=874529332ba, topicName=全因死亡率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262561, encodeId=7bb31262561b3, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310771, encodeId=efcc1310e711e, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395183, encodeId=c43d1395183a8, content=<a href='/topic/show?id=c268e940840' target=_blank style='color:#2F92EE;'>#缺铁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79408, encryptionId=c268e940840, topicName=缺铁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570666, encodeId=f11d15e066667, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008892, encodeId=dc3b10088923d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210115/3496e0581a8a4aec93961012392656e4/fd1698e580a54f3caacf567878f77f53.jpg, createdBy=dd5a5211014, createdName=unlobotomy, createdTime=Wed Aug 18 06:01:17 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1251563, encodeId=054c125156365, content=<a href='/topic/show?id=874529332ba' target=_blank style='color:#2F92EE;'>#全因死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29332, encryptionId=874529332ba, topicName=全因死亡率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262561, encodeId=7bb31262561b3, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310771, encodeId=efcc1310e711e, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395183, encodeId=c43d1395183a8, content=<a href='/topic/show?id=c268e940840' target=_blank style='color:#2F92EE;'>#缺铁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79408, encryptionId=c268e940840, topicName=缺铁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570666, encodeId=f11d15e066667, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008892, encodeId=dc3b10088923d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210115/3496e0581a8a4aec93961012392656e4/fd1698e580a54f3caacf567878f77f53.jpg, createdBy=dd5a5211014, createdName=unlobotomy, createdTime=Wed Aug 18 06:01:17 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1251563, encodeId=054c125156365, content=<a href='/topic/show?id=874529332ba' target=_blank style='color:#2F92EE;'>#全因死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29332, encryptionId=874529332ba, topicName=全因死亡率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262561, encodeId=7bb31262561b3, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310771, encodeId=efcc1310e711e, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395183, encodeId=c43d1395183a8, content=<a href='/topic/show?id=c268e940840' target=_blank style='color:#2F92EE;'>#缺铁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79408, encryptionId=c268e940840, topicName=缺铁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570666, encodeId=f11d15e066667, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008892, encodeId=dc3b10088923d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210115/3496e0581a8a4aec93961012392656e4/fd1698e580a54f3caacf567878f77f53.jpg, createdBy=dd5a5211014, createdName=unlobotomy, createdTime=Wed Aug 18 06:01:17 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1251563, encodeId=054c125156365, content=<a href='/topic/show?id=874529332ba' target=_blank style='color:#2F92EE;'>#全因死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29332, encryptionId=874529332ba, topicName=全因死亡率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262561, encodeId=7bb31262561b3, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310771, encodeId=efcc1310e711e, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395183, encodeId=c43d1395183a8, content=<a href='/topic/show?id=c268e940840' target=_blank style='color:#2F92EE;'>#缺铁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79408, encryptionId=c268e940840, topicName=缺铁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570666, encodeId=f11d15e066667, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Thu Aug 19 00:27:22 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008892, encodeId=dc3b10088923d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210115/3496e0581a8a4aec93961012392656e4/fd1698e580a54f3caacf567878f77f53.jpg, createdBy=dd5a5211014, createdName=unlobotomy, createdTime=Wed Aug 18 06:01:17 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
    2021-08-18 unlobotomy

    学习

    0

相关资讯

Clin Trans Gastroenterology: 腹膜透析患者进行内窥镜检查也可以很安全

腹膜炎是腹膜透析 (PD) 治疗中常见的并发症,会导致很高的死亡率。内窥镜手术在胃肠 (GI) 疾病的诊断和治疗中起着至关重要的作用,此类手术可通过刺激肠壁来

NPJ Biofilms Microbiomes:血液透析患者的肠道菌群失调与死亡率。

肠道微生物多样性和组成与接受维持性血液透析的ESKD患者的全因死亡率密切相关。炎症可能参与了肠道生物失调的发病机制。

J Sex Med:常规血液透析患者和持续不间断腹膜透析患者勃起功能障碍改善情况的比较

勃起功能障碍(ED)是男性慢性肾病(5期CKD)患者经常遇到的性功能障碍并发症之一。在定期透析治疗的患者中,ED可能是由心理因素引起的。目前,血液透析(HD)疗法是透析疗法的首选,只有2%的5期CKD

JASN:血液透析和肾移植患者接种SARS-CoV-2 mRNA疫苗效果如何?

免疫抑制剂治疗可强烈抑制肾移植受者疫苗接种后体液反应,而血液透析患者中,尿毒症状况会降低该反应。

梁卫:血液透析通路进展

90%的肾脏替代治疗患者是通过血液透析治疗,血管通路是透析患者的生命线,而维持透析通路的功能是透析患者住院的首要原因。

JAHA:血液透析患者使用促红细胞生成素治疗与卒中风险

接受血液透析的患者采用促红细胞生成素治疗与卒中或其任何亚型卒中的风险增加无关。

Baidu
map
Baidu
map
Baidu
map